When an antidepressant fails, or causes side effects out of proportion to any benefit, it is natural to want a shortcut to the right choice. GeneSight is a pharmacogenomic test marketed for exactly that moment, and it is increasingly offered in psychiatric offices. The test provides genuinely useful information in certain situations. It is also widely misunderstood as something it is not. Here is a plain account of what it does, what it cannot do, and where the evidence actually stands.
What Pharmacogenomic Testing Is
Pharmacogenomics is the study of how your genes affect the way your body processes medications. Much of that processing happens in the liver, where a family of enzymes breaks drugs down. The genes that build those enzymes vary from person to person. Some variants make an enzyme sluggish, so a medication clears slowly and builds up, which can mean stronger side effects at ordinary doses. Other variants make an enzyme unusually fast, so a medication clears quickly and may never reach a helpful level.
A pharmacogenomic test reads several of these genes from a DNA sample and reports which variants you carry. For GeneSight, the sample is a simple cheek swab collected in the office, and results typically come back within days.
What a GeneSight Report Actually Shows
The report sorts psychiatric medications into categories based on gene and medication interactions. Medications in one category are expected to behave normally for someone with your genetics. Others carry moderate interactions, and a third group carries significant interactions, meaning your profile suggests you may process those drugs unusually fast or unusually slowly. Footnotes explain the reasoning, for example noting that a particular liver enzyme variant may raise blood levels of a specific medication.
Read correctly, this is information about metabolism, meaning how your body handles a drug. It is not information about whether that drug will lift your depression. Those are two different questions, and keeping them separate is the key to using the test well.
What the Test Cannot Do
GeneSight does not identify the right antidepressant. No genetic test can currently predict which medication will relieve your symptoms, because treatment response depends on far more than metabolism. The test does not diagnose depression or any other condition, does not measure how severe your symptoms are, and does not replace a clinician’s judgment about your history and prior treatment. A medication in the significant interaction column is not forbidden, and a medication in the normal column is not guaranteed to work. Prescribers routinely and appropriately use medications from every category, sometimes with closer monitoring.
The Honest State of the Evidence
The evidence is genuinely mixed, and it is fair to say so plainly. The strongest support comes from studies of people whose depression had not improved after previous medication trials. Some of those studies found modest advantages for test-guided prescribing, mostly on secondary measures such as remission, while primary results were often not statistically significant. Regulators have urged caution as well. The Food and Drug Administration has warned that for most medications, the link between genetic variants and antidepressant response is not established. Major psychiatric organizations have taken a similar position, concluding that the evidence does not yet support routine testing for every patient. In short, the metabolism science is solid, while the claims about better treatment outcomes remain much less settled.
When Testing Is Most Useful
The test earns its place after treatment has already been difficult. If more than one antidepressant has failed at a reasonable dose, or if you have had strong side effects at low doses, a metabolism explanation becomes more plausible and more worth checking. Learning that you process a whole class of medications unusually fast or slowly can genuinely change strategy. Testing is far less useful as a first step, before any medication has been tried, and treatment for depression does not need to wait for it.
When to Seek Help
If depression treatment has stalled, the most valuable next step is a thorough review with a psychiatric clinician: what you have tried, for how long, and what happened each time. Genetic testing may be one useful input in that conversation, alongside a fresh look at the diagnosis, sleep, medical conditions, and life circumstances. Persistent symptoms after several medication trials are not a dead end. They are a signal that the treatment plan deserves a careful second look.
Learn more about depression treatment in Miami.